In a new study published in Nature, NIH scientists describe a new type of tuberculosis (TB) treatment that involves manipulating the body’s response to TB bacteria rather than targeting the bacteria themselves, a concept called host-directed therapy. This strategy could be of particular benefit to people infected with drug-resistant TB strains who have limited options for effective antibiotics.